Dysmenorrhea Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034
The 7 major dysmenorrhea markets reached a value of US$ 10.3 Billion in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 18.5 Billion by 2034, exhibiting a growth rate (CAGR) of 5.44% during 2024-2034.
The dysmenorrhea market has been comprehensively analyzed in IMARC's new report titled "Dysmenorrhea Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Dysmenorrhea is a medical condition characterized by painful menstrual periods. Some of the common indications of dysmenorrhea include cramping, lower abdominal pain, back pain, headache, nausea, vomiting, diarrhea, fatigue, etc. The pain can be intermittent or continuous and may start before or during menstruation. The severity of dysmenorrhea symptoms varies from woman to woman and month to month. Some women may also experience emotional indications, such as mood swings or irritability, during their menstrual period. The diagnosis of dysmenorrhea is typically made based on a woman's reported symptoms and medical history. A healthcare provider may ask about the timing and duration of menstrual pain, as well as the severity of indications and any associated factors, including nausea and fatigue. A physical exam is also conducted to check for any underlying medical conditions, such as pelvic inflammatory disease (PID), endometriosis, fibroids, etc., that may be contributing to the menstrual pain. In some cases, several imaging tests, including an ultrasound and MRI, may be suggested to further evaluate the reproductive organs.
The rising prevalence of various associated risk factors, including endometriosis, adenomyosis, fibroids, pelvic inflammatory disease (PID), cervical stenosis, ovarian cysts, etc., is primarily driving the dysmenorrhea market. In addition to this, the inflating utilization of intrauterine devices (IUDs), which can cause irritation and inflammation, thereby leading to increased production of prostaglandins, is also augmenting the market growth. Moreover, the widespread adoption of nonsteroidal anti-inflammatory drugs (NSAIDs), such as ibuprofen, diclofenac, naproxen, ketoprofen, etc., for relieving menstrual cramps as well as reducing inflammation is creating a positive outlook for the market. Apart from this, the escalating usage of hormonal contraceptives, including birth control pills, rings, patches, etc., to help regulate the menstrual cycle and lower the severity of dysmenorrhea symptoms is acting as another significant growth-inducing factor. Additionally, various key players are making extensive investments in research activities to develop drugs that block the formation of prostaglandins, which are hormone-like substances responsible for causing uterine contractions and pain during menstruation. This, in turn, is expected to drive the dysmenorrhea market in the coming years.
IMARC Group's new report provides an exhaustive analysis of the dysmenorrhea market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for dysmenorrhea and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the dysmenorrhea market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the dysmenorrhea market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the dysmenorrhea market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current dysmenorrhea marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the dysmenorrhea market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the dysmenorrhea market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the dysmenorrhea market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of dysmenorrhea across the seven major markets?
What is the number of prevalent cases (2018-2034) of dysmenorrhea by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of dysmenorrhea by gender across the seven major markets?
What is the number of prevalent cases (2018-2034) of dysmenorrhea by type across the seven major markets?
How many patients are diagnosed (2018-2034) with dysmenorrhea across the seven major markets?
What is the size of the dysmenorrhea patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of dysmenorrhea?
What will be the growth rate of patients across the seven major markets?
Dysmenorrhea: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for dysmenorrhea drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the dysmenorrhea market?
What are the key regulatory events related to the dysmenorrhea market?
What is the structure of clinical trial landscape by status related to the dysmenorrhea market?
What is the structure of clinical trial landscape by phase related to the dysmenorrhea market?
What is the structure of clinical trial landscape by route of administration related to the dysmenorrhea market?
The dysmenorrhea market has been comprehensively analyzed in IMARC's new report titled "Dysmenorrhea Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Dysmenorrhea is a medical condition characterized by painful menstrual periods. Some of the common indications of dysmenorrhea include cramping, lower abdominal pain, back pain, headache, nausea, vomiting, diarrhea, fatigue, etc. The pain can be intermittent or continuous and may start before or during menstruation. The severity of dysmenorrhea symptoms varies from woman to woman and month to month. Some women may also experience emotional indications, such as mood swings or irritability, during their menstrual period. The diagnosis of dysmenorrhea is typically made based on a woman's reported symptoms and medical history. A healthcare provider may ask about the timing and duration of menstrual pain, as well as the severity of indications and any associated factors, including nausea and fatigue. A physical exam is also conducted to check for any underlying medical conditions, such as pelvic inflammatory disease (PID), endometriosis, fibroids, etc., that may be contributing to the menstrual pain. In some cases, several imaging tests, including an ultrasound and MRI, may be suggested to further evaluate the reproductive organs.
The rising prevalence of various associated risk factors, including endometriosis, adenomyosis, fibroids, pelvic inflammatory disease (PID), cervical stenosis, ovarian cysts, etc., is primarily driving the dysmenorrhea market. In addition to this, the inflating utilization of intrauterine devices (IUDs), which can cause irritation and inflammation, thereby leading to increased production of prostaglandins, is also augmenting the market growth. Moreover, the widespread adoption of nonsteroidal anti-inflammatory drugs (NSAIDs), such as ibuprofen, diclofenac, naproxen, ketoprofen, etc., for relieving menstrual cramps as well as reducing inflammation is creating a positive outlook for the market. Apart from this, the escalating usage of hormonal contraceptives, including birth control pills, rings, patches, etc., to help regulate the menstrual cycle and lower the severity of dysmenorrhea symptoms is acting as another significant growth-inducing factor. Additionally, various key players are making extensive investments in research activities to develop drugs that block the formation of prostaglandins, which are hormone-like substances responsible for causing uterine contractions and pain during menstruation. This, in turn, is expected to drive the dysmenorrhea market in the coming years.
IMARC Group's new report provides an exhaustive analysis of the dysmenorrhea market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for dysmenorrhea and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the dysmenorrhea market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the dysmenorrhea market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the dysmenorrhea market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current dysmenorrhea marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the dysmenorrhea market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the dysmenorrhea market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the dysmenorrhea market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of dysmenorrhea across the seven major markets?
What is the number of prevalent cases (2018-2034) of dysmenorrhea by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of dysmenorrhea by gender across the seven major markets?
What is the number of prevalent cases (2018-2034) of dysmenorrhea by type across the seven major markets?
How many patients are diagnosed (2018-2034) with dysmenorrhea across the seven major markets?
What is the size of the dysmenorrhea patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of dysmenorrhea?
What will be the growth rate of patients across the seven major markets?
Dysmenorrhea: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for dysmenorrhea drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the dysmenorrhea market?
What are the key regulatory events related to the dysmenorrhea market?
What is the structure of clinical trial landscape by status related to the dysmenorrhea market?
What is the structure of clinical trial landscape by phase related to the dysmenorrhea market?
What is the structure of clinical trial landscape by route of administration related to the dysmenorrhea market?
1 PREFACE
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 DYSMENORRHEA - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (?2018-2023?) and Forecast (?2024-2034?)
4.4 Market Overview (?2018-2023?) and Forecast (?2024-2034?)
4.5 Competitive Intelligence
5 DYSMENORRHEA - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 DYSMENORRHEA - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (?2018-2023?)
7.2.2 Epidemiology Forecast (?2024-2034?)
7.2.3 Epidemiology by Age (?2018-2034?)
7.2.4 Epidemiology by Gender (?2018-2034?)
7.2.5 Epidemiology by Type (?2018-2034?)
7.2.6 Diagnosed Cases (?2018-2034?)
7.2.7 Patient Pool/Treated Cases (?2018-2034?)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (?2018-2023?)
7.3.2 Epidemiology Forecast (?2024-2034?)
7.3.3 Epidemiology by Age (?2018-2034?)
7.3.4 Epidemiology by Gender (?2018-2034?)
7.3.5 Epidemiology by Type (?2018-2034?)
7.3.6 Diagnosed Cases (?2018-2034?)
7.3.7 Patient Pool/Treated Cases (?2018-2034?)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (?2018-2023?)
7.4.2 Epidemiology Forecast (?2024-2034?)
7.4.3 Epidemiology by Age (?2018-2034?)
7.4.4 Epidemiology by Gender (?2018-2034?)
7.4.5 Epidemiology by Type (?2018-2034?)
7.4.6 Diagnosed Cases (?2018-2034?)
7.4.7 Patient Pool/Treated Cases (?2018-2034?)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (?2018-2023?)
7.5.2 Epidemiology Forecast (?2024-2034?)
7.5.3 Epidemiology by Age (?2018-2034?)
7.5.4 Epidemiology by Gender (?2018-2034?)
7.5.5 Epidemiology by Type (?2018-2034?)
7.5.6 Diagnosed Cases (?2018-2034?)
7.5.7 Patient Pool/Treated Cases (?2018-2034?)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (?2018-2023?)
7.6.2 Epidemiology Forecast (?2024-2034?)
7.6.3 Epidemiology by Age (?2018-2034?)
7.6.4 Epidemiology by Gender (?2018-2034?)
7.6.5 Epidemiology by Type (?2018-2034?)
7.6.6 Diagnosed Cases (?2018-2034?)
7.6.7 Patient Pool/Treated Cases (?2018-2034?)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (?2018-2023?)
7.7.2 Epidemiology Forecast (?2024-2034?)
7.7.3 Epidemiology by Age (?2018-2034?)
7.7.4 Epidemiology by Gender (?2018-2034?)
7.7.5 Epidemiology by Type (?2018-2034?)
7.7.6 Diagnosed Cases (?2018-2034?)
7.7.7 Patient Pool/Treated Cases (?2018-2034?)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (?2018-2023?)
7.8.2 Epidemiology Forecast (?2024-2034?)
7.8.3 Epidemiology by Age (?2018-2034?)
7.8.4 Epidemiology by Gender (?2018-2034?)
7.8.5 Epidemiology by Type (?2018-2034?)
7.8.6 Diagnosed Cases (?2018-2034?)
7.8.7 Patient Pool/Treated Cases (?2018-2034?)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (?2018-2023?)
7.9.2 Epidemiology Forecast (?2024-2034?)
7.9.3 Epidemiology by Age (?2018-2034?)
7.9.4 Epidemiology by Gender (?2018-2034?)
7.9.5 Epidemiology by Type (?2018-2034?)
7.9.6 Diagnosed Cases (?2018-2034?)
7.9.7 Patient Pool/Treated Cases (?2018-2034?)
8 DYSMENORRHEA - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 DYSMENORRHEA - UNMET NEEDS
10 DYSMENORRHEA - KEY ENDPOINTS OF TREATMENT
11 DYSMENORRHEA - MARKETED PRODUCTS
11.1 List of Dysmenorrhea Marketed Drugs Across the Top 7 Markets
11.1.1 Naprelan (Naproxen sodium) - Almatica Pharma
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.
12 DYSMENORRHEA - PIPELINE DRUGS
12.1 List of Dysmenorrhea Pipeline Drugs Across the Top 7 Markets
12.1.1 DARE PDM1 - Dare Bioscience
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
12.1.2 Relugolix - Myovant/Takeda
12.1.2.1 Drug Overview
12.1.2.2 Mechanism of Action
12.1.2.3 Clinical Trial Results
12.1.2.4 Safety and Efficacy
12.1.2.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.
13. DYSMENORRHEA - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. DYSMENORRHEA – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 DYSMENORRHEA - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Dysmenorrhea - Market Size
15.2.1.1 Market Size (?2018-2023?)
15.2.1.2 Market Forecast (?2024-2034?)
15.2.2 Dysmenorrhea - Market Size by Therapies
15.2.2.1 Market Size by Therapies (?2018-2023?)
15.2.2.2 Market Forecast by Therapies (?2024-2034?)
15.3 Market Scenario - United States
15.3.1 Dysmenorrhea - Market Size
15.3.1.1 Market Size (?2018-2023?)
15.3.1.2 Market Forecast (?2024-2034?)
15.3.2 Dysmenorrhea - Market Size by Therapies
15.3.2.1 Market Size by Therapies (?2018-2023?)
15.3.2.2 Market Forecast by Therapies (?2024-2034?)
15.3.3 Dysmenorrhea - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Dysmenorrhea - Market Size
15.4.1.1 Market Size (?2018-2023?)
15.4.1.2 Market Forecast (?2024-2034?)
15.4.2 Dysmenorrhea - Market Size by Therapies
15.4.2.1 Market Size by Therapies (?2018-2023?)
15.4.2.2 Market Forecast by Therapies (?2024-2034?)
15.4.3 Dysmenorrhea - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Dysmenorrhea - Market Size
15.5.1.1 Market Size (?2018-2023?)
15.5.1.2 Market Forecast (?2024-2034?)
15.5.2 Dysmenorrhea - Market Size by Therapies
15.5.2.1 Market Size by Therapies (?2018-2023?)
15.5.2.2 Market Forecast by Therapies (?2024-2034?)
15.5.3 Dysmenorrhea - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Dysmenorrhea - Market Size
15.6.1.1 Market Size (?2018-2023?)
15.6.1.2 Market Forecast (?2024-2034?)
15.6.2 Dysmenorrhea - Market Size by Therapies
15.6.2.1 Market Size by Therapies (?2018-2023?)
15.6.2.2 Market Forecast by Therapies (?2024-2034?)
15.6.3 Dysmenorrhea - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Dysmenorrhea - Market Size
15.7.1.1 Market Size (?2018-2023?)
15.7.1.2 Market Forecast (?2024-2034?)
15.7.2 Dysmenorrhea - Market Size by Therapies
15.7.2.1 Market Size by Therapies (?2018-2023?)
15.7.2.2 Market Forecast by Therapies (?2024-2034?)
15.7.3 Dysmenorrhea - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Dysmenorrhea - Market Size
15.8.1.1 Market Size (?2018-2023?)
15.8.1.2 Market Forecast (?2024-2034?)
15.8.2 Dysmenorrhea - Market Size by Therapies
15.8.2.1 Market Size by Therapies (?2018-2023?)
15.8.2.2 Market Forecast by Therapies (?2024-2034?)
15.8.3 Dysmenorrhea - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Dysmenorrhea - Market Size
15.9.1.1 Market Size (?2018-2023?)
15.9.1.2 Market Forecast (?2024-2034?)
15.9.2 Dysmenorrhea - Market Size by Therapies
15.9.2.1 Market Size by Therapies (?2018-2023?)
15.9.2.2 Market Forecast by Therapies (?2024-2034?)
15.9.3 Dysmenorrhea - Access and Reimbursement Overview
16 DYSMENORRHEA - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 DYSMENORRHEA MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 DYSMENORRHEA MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 DYSMENORRHEA - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (?2018-2023?) and Forecast (?2024-2034?)
4.4 Market Overview (?2018-2023?) and Forecast (?2024-2034?)
4.5 Competitive Intelligence
5 DYSMENORRHEA - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 DYSMENORRHEA - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (?2018-2023?)
7.2.2 Epidemiology Forecast (?2024-2034?)
7.2.3 Epidemiology by Age (?2018-2034?)
7.2.4 Epidemiology by Gender (?2018-2034?)
7.2.5 Epidemiology by Type (?2018-2034?)
7.2.6 Diagnosed Cases (?2018-2034?)
7.2.7 Patient Pool/Treated Cases (?2018-2034?)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (?2018-2023?)
7.3.2 Epidemiology Forecast (?2024-2034?)
7.3.3 Epidemiology by Age (?2018-2034?)
7.3.4 Epidemiology by Gender (?2018-2034?)
7.3.5 Epidemiology by Type (?2018-2034?)
7.3.6 Diagnosed Cases (?2018-2034?)
7.3.7 Patient Pool/Treated Cases (?2018-2034?)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (?2018-2023?)
7.4.2 Epidemiology Forecast (?2024-2034?)
7.4.3 Epidemiology by Age (?2018-2034?)
7.4.4 Epidemiology by Gender (?2018-2034?)
7.4.5 Epidemiology by Type (?2018-2034?)
7.4.6 Diagnosed Cases (?2018-2034?)
7.4.7 Patient Pool/Treated Cases (?2018-2034?)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (?2018-2023?)
7.5.2 Epidemiology Forecast (?2024-2034?)
7.5.3 Epidemiology by Age (?2018-2034?)
7.5.4 Epidemiology by Gender (?2018-2034?)
7.5.5 Epidemiology by Type (?2018-2034?)
7.5.6 Diagnosed Cases (?2018-2034?)
7.5.7 Patient Pool/Treated Cases (?2018-2034?)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (?2018-2023?)
7.6.2 Epidemiology Forecast (?2024-2034?)
7.6.3 Epidemiology by Age (?2018-2034?)
7.6.4 Epidemiology by Gender (?2018-2034?)
7.6.5 Epidemiology by Type (?2018-2034?)
7.6.6 Diagnosed Cases (?2018-2034?)
7.6.7 Patient Pool/Treated Cases (?2018-2034?)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (?2018-2023?)
7.7.2 Epidemiology Forecast (?2024-2034?)
7.7.3 Epidemiology by Age (?2018-2034?)
7.7.4 Epidemiology by Gender (?2018-2034?)
7.7.5 Epidemiology by Type (?2018-2034?)
7.7.6 Diagnosed Cases (?2018-2034?)
7.7.7 Patient Pool/Treated Cases (?2018-2034?)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (?2018-2023?)
7.8.2 Epidemiology Forecast (?2024-2034?)
7.8.3 Epidemiology by Age (?2018-2034?)
7.8.4 Epidemiology by Gender (?2018-2034?)
7.8.5 Epidemiology by Type (?2018-2034?)
7.8.6 Diagnosed Cases (?2018-2034?)
7.8.7 Patient Pool/Treated Cases (?2018-2034?)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (?2018-2023?)
7.9.2 Epidemiology Forecast (?2024-2034?)
7.9.3 Epidemiology by Age (?2018-2034?)
7.9.4 Epidemiology by Gender (?2018-2034?)
7.9.5 Epidemiology by Type (?2018-2034?)
7.9.6 Diagnosed Cases (?2018-2034?)
7.9.7 Patient Pool/Treated Cases (?2018-2034?)
8 DYSMENORRHEA - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 DYSMENORRHEA - UNMET NEEDS
10 DYSMENORRHEA - KEY ENDPOINTS OF TREATMENT
11 DYSMENORRHEA - MARKETED PRODUCTS
11.1 List of Dysmenorrhea Marketed Drugs Across the Top 7 Markets
11.1.1 Naprelan (Naproxen sodium) - Almatica Pharma
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.
12 DYSMENORRHEA - PIPELINE DRUGS
12.1 List of Dysmenorrhea Pipeline Drugs Across the Top 7 Markets
12.1.1 DARE PDM1 - Dare Bioscience
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
12.1.2 Relugolix - Myovant/Takeda
12.1.2.1 Drug Overview
12.1.2.2 Mechanism of Action
12.1.2.3 Clinical Trial Results
12.1.2.4 Safety and Efficacy
12.1.2.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.
13. DYSMENORRHEA - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. DYSMENORRHEA – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 DYSMENORRHEA - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Dysmenorrhea - Market Size
15.2.1.1 Market Size (?2018-2023?)
15.2.1.2 Market Forecast (?2024-2034?)
15.2.2 Dysmenorrhea - Market Size by Therapies
15.2.2.1 Market Size by Therapies (?2018-2023?)
15.2.2.2 Market Forecast by Therapies (?2024-2034?)
15.3 Market Scenario - United States
15.3.1 Dysmenorrhea - Market Size
15.3.1.1 Market Size (?2018-2023?)
15.3.1.2 Market Forecast (?2024-2034?)
15.3.2 Dysmenorrhea - Market Size by Therapies
15.3.2.1 Market Size by Therapies (?2018-2023?)
15.3.2.2 Market Forecast by Therapies (?2024-2034?)
15.3.3 Dysmenorrhea - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Dysmenorrhea - Market Size
15.4.1.1 Market Size (?2018-2023?)
15.4.1.2 Market Forecast (?2024-2034?)
15.4.2 Dysmenorrhea - Market Size by Therapies
15.4.2.1 Market Size by Therapies (?2018-2023?)
15.4.2.2 Market Forecast by Therapies (?2024-2034?)
15.4.3 Dysmenorrhea - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Dysmenorrhea - Market Size
15.5.1.1 Market Size (?2018-2023?)
15.5.1.2 Market Forecast (?2024-2034?)
15.5.2 Dysmenorrhea - Market Size by Therapies
15.5.2.1 Market Size by Therapies (?2018-2023?)
15.5.2.2 Market Forecast by Therapies (?2024-2034?)
15.5.3 Dysmenorrhea - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Dysmenorrhea - Market Size
15.6.1.1 Market Size (?2018-2023?)
15.6.1.2 Market Forecast (?2024-2034?)
15.6.2 Dysmenorrhea - Market Size by Therapies
15.6.2.1 Market Size by Therapies (?2018-2023?)
15.6.2.2 Market Forecast by Therapies (?2024-2034?)
15.6.3 Dysmenorrhea - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Dysmenorrhea - Market Size
15.7.1.1 Market Size (?2018-2023?)
15.7.1.2 Market Forecast (?2024-2034?)
15.7.2 Dysmenorrhea - Market Size by Therapies
15.7.2.1 Market Size by Therapies (?2018-2023?)
15.7.2.2 Market Forecast by Therapies (?2024-2034?)
15.7.3 Dysmenorrhea - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Dysmenorrhea - Market Size
15.8.1.1 Market Size (?2018-2023?)
15.8.1.2 Market Forecast (?2024-2034?)
15.8.2 Dysmenorrhea - Market Size by Therapies
15.8.2.1 Market Size by Therapies (?2018-2023?)
15.8.2.2 Market Forecast by Therapies (?2024-2034?)
15.8.3 Dysmenorrhea - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Dysmenorrhea - Market Size
15.9.1.1 Market Size (?2018-2023?)
15.9.1.2 Market Forecast (?2024-2034?)
15.9.2 Dysmenorrhea - Market Size by Therapies
15.9.2.1 Market Size by Therapies (?2018-2023?)
15.9.2.2 Market Forecast by Therapies (?2024-2034?)
15.9.3 Dysmenorrhea - Access and Reimbursement Overview
16 DYSMENORRHEA - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 DYSMENORRHEA MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 DYSMENORRHEA MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
